# Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis

> **NCT05986162** · PHASE1 · UNKNOWN · sponsor: **Biotech Pharmaceutical Co., Ltd.** · enrollment: 44 (estimated)

## Conditions studied

- Dermatomyositis, Adult Type

## Interventions

- **DRUG:** Itolizumab

## Key facts

- **NCT ID:** NCT05986162
- **Lead sponsor:** Biotech Pharmaceutical Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12-30
- **Primary completion:** 2025-05-03
- **Final completion:** 2025-06-25
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2023-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05986162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05986162, "Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05986162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*